Similar articles for PMID: 26847832

Year	Number of Results
2002	2
2003	2
2004	2
2005	2
2006	3
2007	2
2008	3
2009	1
2010	7
2011	3
2012	4
2013	10
2014	6
2015	12
2016	7
2017	9
2018	7
2019	6
2020	6
2021	8
2022	3
2023	1
2025	0

1

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M. Yanagimoto H, et al. Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4. Nutr Cancer. 2016. PMID: 26847832 Clinical Trial.

2

Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.

Hashimoto D, Satoi S, Ishikawa H, Kodera Y, Kamei K, Hirano S, Fujii T, Uemura K, Tsuchida A, Yamada S, Yamamoto T, Hirota K, Sekimoto M. Hashimoto D, et al. Trials. 2022 Feb 12;23(1):135. doi: 10.1186/s13063-021-05934-x. Trials. 2022. PMID: 35151367 Free PMC article.

3

[Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].

Kopchak VM, Kopchak KV, Romaniv IaV. Kopchak VM, et al. Klin Khir. 2006 Feb;(2):23-5. Klin Khir. 2006. PMID: 16826811 Clinical Trial. Russian.

4

Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.

Hashimoto D, Satoi S, Yamamoto T, Yamaki S, Ishida M, Ryota H, Sakaguchi T, Hirooka S, Inoue K, Sekimoto M. Hashimoto D, et al. Surg Today. 2021 Nov;51(11):1872-1876. doi: 10.1007/s00595-021-02308-3. Epub 2021 Jun 4. Surg Today. 2021. PMID: 34086127

5

[A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].

Ichikawa Y, Yamada D, Eguchi H, Iwagami Y, Noda T, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Tatsumi M, Takeyari M, Mori M, Doki Y. Ichikawa Y, et al. Gan To Kagaku Ryoho. 2017 Nov;44(12):2014-2016. Gan To Kagaku Ryoho. 2017. PMID: 29394852 Japanese.

6

The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.

Kato A, Naiki-Ito A, Naitoh I, Hayashi K, Nakazawa T, Shimizu S, Nishi Y, Okumura F, Inoue T, Takada H, Kondo H, Yoshida M, Takahashi S, Joh T. Kato A, et al. Hum Pathol. 2018 Apr;74:92-98. doi: 10.1016/j.humpath.2018.01.009. Epub 2018 Jan 12. Hum Pathol. 2018. PMID: 29339176

7

Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.

Suenaga S, Kuramitsu Y, Kaino S, Maehara S, Maehara Y, Sakaida I, Nakamura K. Suenaga S, et al. Anticancer Res. 2014 Jan;34(1):141-6. Anticancer Res. 2014. PMID: 24403454

8

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.

Park SJ, Kim H, Shin K, Hong TH, Suh JH, Lee MA. Park SJ, et al. BMC Cancer. 2021 Nov 3;21(1):1176. doi: 10.1186/s12885-021-08887-1. BMC Cancer. 2021. PMID: 34732161 Free PMC article.

9

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Poplin E, et al. J Clin Oncol. 2013 Dec 10;31(35):4453-61. doi: 10.1200/JCO.2013.51.0826. Epub 2013 Nov 12. J Clin Oncol. 2013. PMID: 24220555 Clinical Trial.

10

Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.

Mori S, Aoki T, Sakuraoka Y, Shimizu T, Yamaguchi T, Park KH, Matsumoto T, Shiraki T, Iso Y, Kubota K. Mori S, et al. Cancer Chemother Pharmacol. 2021 Jul;88(1):109-120. doi: 10.1007/s00280-021-04267-5. Epub 2021 Apr 7. Cancer Chemother Pharmacol. 2021. PMID: 33825991

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 26847832

97 results

Results by year